A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
- PMID: 11309497
- PMCID: PMC33205
- DOI: 10.1073/pnas.091021198
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
Abstract
The peroxisome proliferator-activated receptors (PPARs) are dietary lipid sensors that regulate fatty acid and carbohydrate metabolism. The hypolipidemic effects of the fibrate drugs and the antidiabetic effects of the glitazone drugs in humans are due to activation of the alpha (NR1C1) and gamma (NR1C3) subtypes, respectively. By contrast, the therapeutic potential of the delta (NR1C2) subtype is unknown, due in part to the lack of selective ligands. We have used combinatorial chemistry and structure-based drug design to develop a potent and subtype-selective PPARdelta agonist, GW501516. In macrophages, fibroblasts, and intestinal cells, GW501516 increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux. When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin. Our results suggest that PPARdelta agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascular disease associated with the metabolic syndrome X.
Figures
Similar articles
-
Quercetin up-regulates expressions of peroxisome proliferator-activated receptor γ, liver X receptor α, and ATP binding cassette transporter A1 genes and increases cholesterol efflux in human macrophage cell line.Nutr Res. 2013 Feb;33(2):136-43. doi: 10.1016/j.nutres.2012.11.010. Epub 2012 Dec 27. Nutr Res. 2013. PMID: 23399664
-
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2289-94. doi: 10.1161/ATVBAHA.112.247890. Epub 2012 Jul 19. Arterioscler Thromb Vasc Biol. 2012. PMID: 22814748 Clinical Trial.
-
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.Cardiovasc Diabetol. 2005 Sep 16;4:14. doi: 10.1186/1475-2840-4-14. Cardiovasc Diabetol. 2005. PMID: 16168052 Free PMC article. Review.
-
The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.Mol Endocrinol. 2003 Dec;17(12):2477-93. doi: 10.1210/me.2003-0151. Epub 2003 Oct 2. Mol Endocrinol. 2003. PMID: 14525954
-
Peroxisome proliferator-activated receptors: from genes to physiology.Recent Prog Horm Res. 2001;56:239-63. doi: 10.1210/rp.56.1.239. Recent Prog Horm Res. 2001. PMID: 11237216 Review.
Cited by
-
Complementary information concerning the suspected interindividual transmission of GW1516, a substance prohibited in sport, through intimate contact: a case report.Forensic Toxicol. 2024 May 5. doi: 10.1007/s11419-024-00689-x. Online ahead of print. Forensic Toxicol. 2024. PMID: 38704758
-
Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease.Biomedicines. 2023 Oct 3;11(10):2696. doi: 10.3390/biomedicines11102696. Biomedicines. 2023. PMID: 37893070 Free PMC article. Review.
-
The TICE Pathway: Mechanisms and Potential Clinical Applications.Curr Atheroscler Rep. 2023 Oct;25(10):653-662. doi: 10.1007/s11883-023-01147-6. Epub 2023 Sep 22. Curr Atheroscler Rep. 2023. PMID: 37736845 Review.
-
Peroxisome proliferator-activated receptors as therapeutic target for cancer.J Cell Mol Med. 2023 Sep 12;28(5):e17931. doi: 10.1111/jcmm.17931. Online ahead of print. J Cell Mol Med. 2023. PMID: 37700501 Free PMC article. Review.
-
Integrative omics-analysis of lipid metabolism regulation by peroxisome proliferator-activated receptor a and b agonists in male Atlantic cod.Front Physiol. 2023 Mar 22;14:1129089. doi: 10.3389/fphys.2023.1129089. eCollection 2023. Front Physiol. 2023. PMID: 37035678 Free PMC article.
References
-
- Willson T M, Brown P J, Sternbach D D, Henke B R. J Med Chem. 2000;43:527–550. - PubMed
-
- Xu H E, Lambert M H, Montana V G, Parks D J, Blanchard S G, Brown P J, Sternbach D D, Lehmann J M, Wisely G B, Willson T M, et al. Mol Cell. 1999;3:397–403. - PubMed
-
- Mangelsdorf D J, Evans R M. Cell. 1995;83:841–850. - PubMed
-
- Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Endocrinology. 1996;137:354–366. - PubMed
-
- Lichtenstein A H, Kennedy E, Barrier P, Ernst N D, Grundy S M, Leveille G A, Van Horne L, Williams C L, Booth S L. Nutr Rev. 1998;56:S3–S28. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases